The civic record
Read. Follow. Verify.Louisiana requires health insurers to cover oral anti-cancer drugs on par with intravenous treatments
Last action · June 8, 2026: Effective date: 08/01/2026.Sponsors: Aimee Adatto Freeman and 1 other
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
What This Bill Does
Health insurance issuers in Louisiana must provide coverage for prescribed orally administered anti-cancer medications on terms no less favorable than intravenously administered or injected cancer treatments, prohibiting higher cost-sharing, prior authorization, or s.
Enrollees using oral cancer medications gain protection from higher out-of-pocket costs and specialty-tier restrictions that previously made pills more expensive than intravenous treatments, with compliance achieved if total cost-sharing is capped at no more than $180 per filled prescription.
Who It Affects
Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.
covered person
Enrollees receiving cancer treatment are protected from higher cost-sharing and restrictive utilization management for oral medications compared to intravenous treatments.
health insurance issuer
Insurers must adjust coverage guidelines, cost-sharing structures, and formulary placements to ensure parity between oral and intravenous anti-cancer medications.
Key Facts
You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.
Frequently Asked Questions
What does this law change for cancer patients taking oral medications?
Is there a limit on how much an insured person can be charged per prescription?
Does this law apply to employer-sponsored self-funded health plans?
What else do you want to know?
News Coverage
Follow the record
Votes, people, money & the original sourceWhere This Stands
Current status: Signed into law.
Procedural history
28 actions- Jun 8, 2026HouseEnrolledSigned by the Governor. Becomes Act No. 833.
- Jun 8, 2026HouseEffective date: 08/01/2026.
- Jun 1, 2026SenateEnrolledSigned by the President of the Senate.
- Jun 1, 2026HouseSent to the Governor for executive approval.
- May 31, 2026HouseEnrolledEnrolled and signed by the Speaker of the House.
- May 29, 2026HouseIntroducedRead by title, roll called, yeas 97, nays 0, Senate amendments concurred in.
Show 22 earlier actions
- May 27, 2026HouseScheduled for concurrence on 05/29/2026.
- May 26, 2026SenateFloorRules suspended. Senate floor amendments read and adopted. Read by title, passed by a vote of 37 yeas and 0 nays, and ordered returned to the House. Motion to reconsider tabled.
- May 26, 2026HouseReceived from the Senate with amendments.
- May 25, 2026SenateFloorReported without Legislative Bureau amendments. Read by title and passed to third reading and final passage.
- May 21, 2026SenateFloorCommittee amendments read and adopted. Read by title and referred to the Legislative Bureau.
- May 20, 2026SenateReported with amendments.
- May 13, 2026SenateCommitteeRead second time by title and referred to the Committee on Insurance.
- May 12, 2026SenateReceived in the Senate. Read first time by title and placed on the Calendar for a second reading.
- May 11, 2026HouseCalled from the calendar.
- May 11, 2026HouseFloorRead third time by title, amended, roll called on final passage, yeas 93, nays 0. Finally passed, title adopted, ordered to the Senate.
- May 7, 2026HouseIntroducedRead by title, returned to the calendar.
- May 7, 2026HouseNotice given.
- May 7, 2026HouseScheduled for floor debate on 05/11/2026.
- May 6, 2026HouseFloorRead by title, amended, ordered reengrossed, passed to 3rd reading.
- May 6, 2026HouseScheduled for floor debate on 05/07/2026.
- May 5, 2026HouseReported with amendments (18-0).
- Apr 9, 2026HouseIntroducedRead by title, amended, ordered engrossed, recommitted to the Committee on Appropriations.
- Apr 8, 2026HouseReported with amendments (10-0).
- Mar 9, 2026HouseIntroducedRead by title, under the rules, referred to the Committee on Insurance.
- Feb 27, 2026HousePrefiled.
- Feb 27, 2026HouseCommitteeUnder the rules, provisionally referred to the Committee on Insurance.
- Feb 27, 2026HouseFirst appeared in the Interim Calendar on 2/27/2026.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →Lobbying Activity
No state lobbying filings in our records match this bill. Federal lobbying reports (LDA) cover Congress, so they are not listed on state bills.
Full breakdown
Who this bill affects and the strongest case for and against it, written only from the bill’s own text.
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Oral and Intravenous Cancer Treatment Parity
The state establishes a regulatory requirement forcing health insurance plans to treat oral anti-cancer prescriptions on equal terms with intravenous treatments, eliminating higher cost burdens on pill-based therapies.
Connected Entities
Sources
www.legis.la.gov
Analysis Score
0–100- Significance85How much this matters to a regular citizen
- Controversy15Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz40Current news / social attention level
Publisher tools